Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Jul 1, 2026
    • Secondary endpoints: 1 to 2
    v18
  2. Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Jun 2016 to Aug 2016
    v17
  3. Primary completion date: Dec 2014 to Dec 2015
    • Study completion date: Jun 2015 to Jun 2016
    v16
  4. Re-verified, no change to tracked fieldsv15
  5. Primary completion date: Dec 2013 to Dec 2014
    • Study completion date: Jun 2014 to Jun 2015
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 30
    • Site details revised
    v13
  2. Primary completion date: Dec 2012 to Dec 2013
    • Study completion date: Jun 2013 to Jun 2014
    v12
  3. Primary completion date: Dec 2011 to Dec 2012
    • Study completion date: Jun 2012 to Jun 2013
    v11
  4. Primary completion date: Jan 2010 to Dec 2011
    • Study completion date: Jan 2010 to Jun 2012
    v10
  5. 2 versions Re-verified since Jul 24, 2009, no change to tracked fieldsv8-v9
  6. Primary and study completion dates: Jan 2009 to Jan 2010v7
  7. Interventions: paclitaxel, gemcitabine and oxaliplatin (Drug) to paclitaxel, gemcitabine, and oxaliplatin (Drug)
    • Eligibility criteria expanded, about 5 words
    v6
  8. Re-verified, no change to tracked fieldsv5
  9. Enrollment target: 20v4 Show 6 more changesShow less
    • Primary completion date: Jan 2009
    • Study completion date: Apr 2008 to Jan 2009
    • Interventions: Gemcitabine, oxaliplatin, paclitaxel (Drug) to paclitaxel, gemcitabine and oxaliplatin (Drug)
    • Eligibility criteria revised
    • Site contact updated
    • Study arms: 0 to 1
  10. Study completion date: Apr 2006 to Apr 2008v3
  11. Study completion date: Apr 2006v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Trial Details
NCT Number NCT00183820
Lead Sponsor University of Southern California
Collaborators: Sanofi
Conditions
(from sponsor)		 Testicular Cancer, Germ Cell Neoplasm
Related terms Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov